Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Subdural hematoma medical therapy
Introduction
Overview
Overview
Surgery is the mainstay of treatment for subdural hematoma. Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.
Medical Therapy
Medical Therapy
- Surgery is the mainstay of treatment for subdural hematoma.
- Pharmacologic medical therapies for subdural hematoma include corticosteroids, atorvastatin, tranexamic acid, etizolam, and ACE inhibitor.[1][2][3][4][5]
- In patients with anticoagulation problem we have to correct the coagulation system:
- Prothrombin complex concentrate (PCC) for patients who use warfarin or other vitamin K antagonist (VKA)
- Idarucizumab for patients who use dabigatran
- Andexanet alfa for patients who use direct factor Xa inhibitor
- Protamine sulfate for patients who use heparin
References
References
- ↑ Thotakura, AmitKumar; Marabathina, NageswaraRao (2018). “The role of medical treatment in chronic subdural hematoma”. Asian Journal of Neurosurgery. 13 (4): 976. doi:10.4103/ajns.AJNS_13_17. ISSN 1793-5482.
- ↑ Ostermann, Helmut; von Heymann, Christian (2019). “Prothrombin complex concentrate for vitamin K antagonist reversal in acute bleeding settings: efficacy and safety”. Expert Review of Hematology. doi:10.1080/17474086.2019.1624520. ISSN 1747-4086.
- ↑ Vornicu, Ovidiu; Larock, Anne-Sophie; Dincq, Anne-Sophie; Douxfils, Jonathan; Dogné, Jean-Michel; Mullier, François; Lessire, Sarah (2017). “Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures”. Expert Opinion on Biological Therapy. 17 (10): 1275–1296. doi:10.1080/14712598.2017.1349749. ISSN 1471-2598.
- ↑ Powell, Jason; Taylor, James; Garland, Scott G. (2019). “Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent”. Annals of Pharmacotherapy: 106002801983520. doi:10.1177/1060028019835209. ISSN 1060-0280.
- ↑ Derbalah, Abdallah; Duffull, Stephen; Newall, Fiona; Moynihan, Katie; Al-Sallami, Hesham (2019). “Revisiting the Pharmacology of Unfractionated Heparin”. Clinical Pharmacokinetics. doi:10.1007/s40262-019-00751-7. ISSN 0312-5963.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.